Retrospective-Prospective Registry of Immune-Mediated Type 1 Diabetes in Solid Tumor Patients Treated with Immune Checkpoint Inhibitors
Phase: Observational, retrospective-prospective, pharmacological study
Principal Investigator: Dott.ssa Indini Alice
Main Facility: Oncologia medica melanomi
Drug: Farmaco ICIs (Immune Checkpoint Inhibitors)
Pathologies: Melanoma
This study aims to evaluate the clinical and oncological characteristics of patients who develop type 1 diabetes mellitus during treatment with immune checkpoint inhibitors (ICI-T1DM).
Immune checkpoint inhibitors (ICIs) are a widely used therapeutic strategy in the treatment of solid tumors. Their mechanism of action, based on stimulation of the immune system, can induce immune-related adverse events (irAEs), including endocrinopathies.
Among the rarer but clinically significant endocrinopathies is the onset of ICI-T1DM, characterized by significant long-term morbidity. This form, defined as immune-mediated diabetes, is considered more aggressive than classic type 1 diabetes. With improved survival rates and the expanding use of ICIs even in early-stage settings, adverse events such as ICI-T1DM are becoming increasingly significant and require special attention.
The primary objective of the study is to analyze the patterns of onset, clinical management, and progression of ICI-T1DM in patients with solid tumors treated with ICIs.
The primary endpoint is to evaluate the clinical, biochemical, and immunological characteristics of patients at the time of ICI-T1DM diagnosis.
Last update: 13/07/2026